Screener
Syndax Pharmaceuticals SNDX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
FAQ
- What is Syndax Pharmaceuticals's cash & equivalents?
- Syndax Pharmaceuticals (SNDX) reported cash & equivalents of $130.89M in Q1 2026.
- How has Syndax Pharmaceuticals's cash & equivalents changed year-over-year?
- Syndax Pharmaceuticals's cash & equivalents decreased by 15.0% year-over-year, from $153.99M to $130.89M.
- What is the long-term trend for Syndax Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's cash & equivalents has grown at a 3.2% compound annual growth rate (CAGR), from $115.24M to $134.93M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Syndax Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude